Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Suzuken Co ( (JP:9987) ) just unveiled an announcement.
Suzuken Co., Ltd. has revised its full-year consolidated financial results forecast for the fiscal year ended March 31, 2025. The revision reflects an increase in net sales driven by new drugs and COVID-19-related products, leading to higher operating and net income than previously anticipated. This adjustment indicates a positive impact on Suzuken’s financial performance and suggests strengthened market positioning due to effective cost management and strategic product offerings.
More about Suzuken Co
Suzuken Co., Ltd. operates in the pharmaceutical industry, focusing on the distribution of pharmaceutical products, including specialty drugs and COVID-19-related products. The company is listed on the Prime Markets of the Tokyo and Nagoya Stock Exchanges, as well as the Sapporo Securities Exchange.
YTD Price Performance: 20.58%
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.02B
Find detailed analytics on 9987 stock on TipRanks’ Stock Analysis page.